NICE recommends Amryt’s Filsuvez for rare skin disorder
Around 670 people in England with epidermolysis bullosa will benefit from the treatment
Read More
Tag: dermatology
Almirall analyses wider well-being in dermatology study
The trial will monitor patients across Europe for 24 months as they are treated with tildrakizumab
Read More
Dupixent hits all endpoints in prurigo nodularis trial
Dupixent significantly reduced itch and skin lesions compared to placebo in the investigational trial setting
Read More
Novartis UK signs digital partnership with Cievert for chronic disease management
Initiative is aiming to support NHS patient care in rheumatology and dermatology
Read More
QiC Dermatology now open for entries
QiC Programmes are run by PMGroup and were first launched in 2011 to bring the NHS, industry and patient groups closer together.
Read More
LEO Pharma completes Bayer prescription dermatology business acquisition
Under the terms of the agreement, LEO Pharma has now acquired the global product rights for Bayer’s global prescription dermatology business with the exception of Afghanistan and Pakistan.
Read More
Novartis to sell Sandoz assets to Aurobindo for $900m
Novartis is selling parts of its generics business Sandoz to Aurobindo in a deal worth at least $900 million.
Read More
Skin conditions cost NHS £723m a year
New research shows that more than three million primary care hours are spent on skin conditions, at a cost to the NHS of £723 million each year.
Read More
NICE green light for Lilly’s psoriasis drug
Patients with plaque psoriasis should be able to get routine access to Eli Lilly’s Taltz on the NHS within the next three months if they meet certain eligibility criteria.
Read More
- MIT’s new MRI brain light-detecting technique could support brain cell studies
- PharmaTimes MSEA and NIEA awards are open for entry
- BBSRC invests £48m in Babraham Institute to advance lifelong health research
- NHS reduces long waits for cancer care and achieves faster ambulance responses
- MHRA’s AI Airlock to address challenges for regulating AI medical devices
